Oncology Precision Medicine Market Trends, Business Opportunities, Strategies and Forecast 2031A Chapter by BIS ResearchThe global oncology precision medicine market was valued at $45,174.2 million in 2020 and is expected to reach $1,28,891.6 million by 2031, growing at a CAGR of 10.05% during the forecast period 2021-The precision medicine concept is a systematic process aiming to achieve victory over a disease such as cancer. Cancer is the major focus of various precision medicine initiatives, and precision oncology centers around matching the most accurate and precise treatment to each cancer patient on the basis of an individual's matching genetic profile that could ultimately let them benefit from the treatment offered. The global oncology precision medicine market was valued at $45,174.2 million in 2020 and is expected to reach $1,28,891.6 million by 2031, growing at a CAGR of 10.05% during the forecast period 2021-2031. Factors fueling the growth of the market include increasing incidence of cancer globally, decreasing trial and error-based drug prescription through pharmacogenomics, increasing usage of predictive biomarkers for cancer diagnostics, and rapid technological advancements related to oncology precision medicine. Oncology Precision Medicine Market: SegmentationThe market is segmented between Ecosystem and Application, further it is segmented by Regions. Market Segmentation • Ecosystem - Precision Therapeutics, Applied Sciences, Digital Health and Information Technology, Precision Diagnostics • Application - Solid Tumor and Hematological Malignancies Regional Segmentation • North America: U.S., Canada • Europe: Germany, France, Italy, U.K., Spain, and Rest-of- Europe • Asia-Pacific: Japan, China, India, Australia, South Korea, and Rest-of-Asia-Pacific • Latin America: Brazil, Mexico, and Rest-of-Latin America • Rest-of-the-World Global Oncology Precision Medicine Market, Market DynamicsCompetitive Landscape The exponential rise in the prevalence of cancer globally has created a buzz among companies to invest in oncology precision medicine. Based on region, North America holds the largest share, owing to rising cancer prevalence and improvised regulatory policies pertaining to precision oncology in the region. However, the Asia-Pacific and Europe regions are anticipated to grow at the fastest CAGR during the forecast period. Key Companies Profiled Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Illumina, Inc., Pacific Biosciences of California, Inc., PerkinElmer Inc., QIAGEN, Thermo Fisher Scientific Inc., BGI Group, ASURAGEN, INC., Almac Group Ltd., MDxHealth, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Myriad Genetics, Inc., OPKO Health, Inc., Quest Diagnostics Incorporated, Novartis AG Key Questions Answered in this Report:• How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each segment? Request Sample - https://bisresearch.com/requestsample?id=1270type=download BIS Related Studies Precision Cardiology Market - A Global and Regional Analysis © 2022 BIS Research |
Stats
25 Views
Added on May 11, 2022 Last Updated on May 11, 2022 Tags: Oncology Precision Medicine Mark, Oncology Precision Medicine Mark, Oncology Precision Medicine indu Author
|